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Introduction
Headache is an omniscient illness with a lifetime preva-
lence rate reaching 90% (1). There are several types of 
headaches, so that 150 diagnostic headache categories have 
been defined. Most patients arriving in the emergency de-
partment (ED), suffering from severe headache require a 
rapid and an effective release from their symptoms (2, 3). 
There are frequent guidelines for management of acute 
headaches that generally recommended several different 
agents, such as dihydroergotamine, triptans, phenothi-
azines, opioids or nonsteroidal anti-inflammatory drugs 
(NSAIDs) (4-6). Ketorolac is one of NSAIDs which has 
been tested several times in randomized clinical trials and 
recommended as an effective agent for patients with pain 
(7-11). However the search is still on. Ketorolac accepted 
as an alternative to non-steroidal analgesics and also opi-
oid in controlling moderate to severe pain (12). About 2 
decades before, it was thought that although ketorolac has 
a considerable analgesic effect, but has restriction for ap-
plication as a fast pain abortive in the ED (13). Some other 
believed that this drug could be considered as a useful ad-
juvant, or alternative for opioids in subjects with moder-
ate to severe pain (14, 15). Thinking that different types 
of headaches involve the same inflammatory component 
in their pathophysiology, ketorolac is expected to be ef-
fective. This agent is an efficient non-narcotic pain killer 
with intermediate anti-inflammatory effect. Therefore 
consider as a preferable option for pain management of 
different type of primary headache cases admitted to the 
ED (16-19). Current study was conducted with the aim 
of ketorolac efficacy measurement as a non-narcotic anti-
inflammatory pain killer agent for controlling the primary 
headache in of patients presented to the ED with all types 
of primary headaches.
Methods
Patients with any kind of primary headache admitted to 
the ED of Shohadaye Tajrish hospital in Tehran, Iran were 
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Abstract
Objective: One of nonsteroidal anti-inflammatory drugs (NSAIDs) named as ketorolac 
is frequently used to relieve acute pain. Current study was conducted with the aim 
of ketorolac efficacy measurement as a pain killer agent for controlling the primary 
headache in emergency departments.
Methods: In this study, we enrolled 50 patients with primary headache who received 
60 mg ketorolac intravenously as a slow infusion in about 10 minutes. Pain scores 
were evaluated with visual analog scale (VAS) on arrival and also 1 hour and 2 hours 
after ketorolac infusion. Statistical analysis was performed on collected data by using 
Wilcoxon and Mann-Whitney tests to assess the differences in VAS pain scores. 
Results: Decreasing the VAS more than 3 points from the arrival until 1 hour (P < 0.001), 
and more than 5 points from the arrival until 2 hours after ketorolac administration 
(P < 0.001) were seen. Those with history of analgesic use before admission in 
emergency department in comparison with the others did not accompany with more 
decline in pain score after 1 hour (P = 0.34) or 2 hours (P = 0.92).
Conclusion: It seems that ketorolac is assured, safe and well tolerated agent for pain 
control in patients presented with primary headache to the emergency departments. 
Based on the results achieved in this study, ketorolac illustrates its perceptible effects 
within 1 hour after administration that even more prominent after 2 hours.
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participated in this study.
All patients in 18-60 years old age range with complaint of 
moderate to severe headache (pain score>5) that indicated 
for intravenous treatment were included.
Patients with positive history for any of the following 
items were excluded: breast feeding, pregnancy, active 
peptic ulcer disease, coagulopathy, inflammatory bowel 
disease, renal failure or hepatic failure. 
The pain scores were recorded on arrival based on visual 
analog scale (VAS) and those with the score more than 5 
received 60 mg ketorolac intravenously as a slow infusion 
in about 10 minutes. All were considered for any possible 
side effects including irritability, itching, pain on injec-
tion, hypertension, tachycardia, nausea and/or vomiting. 
If any happened then process had to be stop. One and 2 
hours after injection of medication to the patients, they 
were asked about their pain scores again. Decreasing more 
than 3 scores in pain scale was considered as proper re-
sponse.
SPSS version 22 was used for performing the statistical 
analysis. For describing continuous variables mean, medi-
an, interquartile range, and standard deviation were used. 
For analyzing the differences in registered pain scores, 
Mann-Whitney U and Wilcoxon tests were used. For de-
scribing categorical variables, frequency and percentage 
were used. P ≤ 0.05 was considered as meaningful level. 
Results
Fifty patients with the mean age of 30.14±11.4 years old 
were involved. From the participants, 22 patients (44%) 
were male and 28 patients (56%) were female. It should be 
mentioned that 28 (56%) patients did not use any kind of 
analgesic before arrival to the ED. From other 22 patients 
(44%) who had already taken other medication, almost 
all of them had used acetaminophen or different type 
of NSAIDs. The mean ± standard deviation period from 
taking other medication to ketorolac administration was 
2.77 ± 1.9 hours. The VAS median reduced significantly 
from 8.0 ± 2.0 to 5.0 ± 4.0 after 1 hour and to 3.0 ± 2.0 after 
2 hours (Figure 1).
Significant VAS drop (>3 points, >35%) was reported 
from baseline until 1 hour after ketorolac administra-
tion (Wilcoxon test Z = –6.1; P < 0.001). One hour later, 
more decline (>6 points, >60%) was seen (Wilcoxon test 
Z = –6.1; P < 0.001). There was also a statistical significant 
difference between VAS at 1 hour and 2 hours after drug 
administration (Wilcoxon test Z = –4.2; P < 0.001).
To assess the possible effect of medication use before ar-
rival to the ED, enrolled patients were divided into 2 
groups according to taking previous medication or not. 
Statistical analysis did not reveal significant difference be-
tween the groups. The P values related to comparison of 
VAS between two groups at baseline, 1 hour and 2 hours 
after ketorolac administration were 0.51, 0.62, and 0.69, 
respectively. There was also no significant statistical dif-
ference between the groups in terms of VAS reducing 1 
hour (P = 0.34) and 2 hours (P = 0.92) after ketorolac ad-
ministration (Figure 2).
Discussion
Based on findings of the current study, significant decreas-
ing of pain score was seen from baseline to 1 hour and 2 
hours after ketorolac administration. This improvement 
was obtained in almost all cases except two patients whose 
VAS did not improve well even after 2 hours. The intrave-
nous ketorolac accompanied with significant success rate 
so that lead to more than 3 points decline in VAS after one 
hour and more than 5 points after 2 hours.
All patients were observed for about 6 hours after drug 
administration for possible short time side effects and also 
replace of headache. Fortunately, there was no case of such 
complications, which can confirm the safety and effec-
Figure 1. Minimum, maximum, median and interquartile range of 
visual analogue scale at baseline, 1 hour and 2 hours after ketorolac 
intravenous infusion.
Figure 2. Minimum, maximum, median and interquartile range 
of visual analogue scale at baseline, one hour and two hours after 
ketorolac intravenous infusion for patients who took analgesic before 
arrival and those who did not.
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tiveness of intravenous ketorolac in the enrolled patients. 
According the rigorous intended inclusion and exclusion 
criteria for selecting patients in this study, results should 
be interpreted with caution. 
Parenteral ketorolac is frequently used for abortive treat-
ment of moderate to severe headache. As a NSAID, ke-
torolac mechanism of action is inhibition of prostaglandin 
synthesis by non-selective inhibition of cyclooxygenase 
enzyme.
Ketorolac were used in several studies, so supporting and 
opposing comments has been proposed. In a pilot study, 
60 mg intramuscular ketorolac was administered to twelve 
patients with headache crisis. All patients showed statisti-
cally significant improvement on their McGill pain ques-
tionnaire and authors recommended this drug as a pos-
sible useful agent in the treatment of such patients (20). 
Intravenous ketorolac was compared with nasal sumat-
riptan in a prospective double-blind study that performed 
on patients with complaint of migraine headache. Authors 
reported that although both drugs significantly reduced 
the pain, but intravenous ketorolac was more effective 
than nasal sumatriptan in this regard (21).
In a controlled trial, intramuscular ketorolac was com-
pared with meperidine plus promethazine, and also nor-
mal saline as a placebo in tension headache. The authors 
reported that ketorolac was superior to placebo at 0.5 and 
1 hour and superior to meperidine at 2 hours (22). Inter-
estingly, these authors had conducted the same study on 
acute headache crises 2 years earlier and had reported that 
using all three options could lead to significant pain con-
trol, but the amount did not differ among them (23).
In a non-interventional non-randomized survey on pain 
management, intramuscular ketorolac and oral ibupro-
fen were compared. The authors of the mentioned study 
concluded that both option produced similar pain relief 
in dealing with acute pain in ED. They believed that ke-
torolac did not have certain superiority than ibuprofen for 
this aim (24).
In another study which performed on patients presenting 
with migraine headache, it was shown that one dose injec-
tion of ketorolac can lead to significant decrease in head-
ache symptoms after 1 hour in most participants (25).
In a randomized trial for comparing the effectiveness of 
intravenous ketorolac, metoclopramide, and valproate so-
dium for management of acute migraine headache, it was 
concluded that ketorolac was superior to valproate sodi-
um but less efficacious than metoclopramide (26).
Intravenous ketorolac was also compared with intrave-
nous diphenhydramine plus metoclopramide for treat-
ment of some primary headaches. The study concluded 
that for adults who presented to an ED with non-migraine, 
non-cluster primary headaches, intravenous diphenhydr-
amine plus metoclopramide have better efficacy than in-
travenous ketorolac (27).
Using a standard measuring tool like VAS and the precise 
selection of patients can be considered as the strengths in 
this study. On the other hand, short time follow up pe-
riod is one of the limitations. Considering a control group, 
escalating doses, larger population, and describing non-
responders patients to ketorolac are recommended for 
future research.
Conclusion
It seems that ketorolac is assured, safe and well tolerated 
agent for pain control in patients presented with primary 
headache to the EDs. Based on the results achieved in this 
study, ketorolac illustrates its perceptible effects within 1 
hour after administration that even more prominent after 
2 hours.
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